Literature DB >> 29759728

Synthesis and evaluation of a ring-constrained Hsp90 C-terminal inhibitor that exhibits neuroprotective activity.

Zheng Zhang1, Zhenyuan You2, Rick T Dobrowsky2, Brian S J Blagg3.   

Abstract

KU-596 is a second-generation C-terminal heat shock protein 90 KDa (Hsp90) modulator based on the natural product, novobiocin. KU-596 has been shown to induce Hsp70 levels and manifest neuroprotective activity through induction of the heat shock response. A ring-constrained analog of KU-596 was designed and synthesized to probe its binding orientation and ability to induce Hsp70 levels. Compound 2 was found to exhibit comparable or increased activity compared to KU-596, which is under clinical investigation for the treatment of neuropathy.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Hsp90 C-terminal inhibitor; Neuroprotective; Novologue; Ring-constrained

Mesh:

Substances:

Year:  2018        PMID: 29759728      PMCID: PMC6119633          DOI: 10.1016/j.bmcl.2018.03.071

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  28 in total

1.  Alternative approaches to Hsp90 modulation for the treatment of cancer.

Authors:  Jessica A Hall; Leah K Forsberg; Brian S J Blagg
Journal:  Future Med Chem       Date:  2014-09       Impact factor: 3.808

2.  Synthesis and evaluation of novologues as C-terminal Hsp90 inhibitors with cytoprotective activity against sensory neuron glucotoxicity.

Authors:  Bhaskar Reddy Kusuma; Liang Zhang; Teather Sundstrom; Laura B Peterson; Rick T Dobrowsky; Brian S J Blagg
Journal:  J Med Chem       Date:  2012-06-15       Impact factor: 7.446

3.  Novel C-terminal Hsp90 inhibitor for head and neck squamous cell cancer (HNSCC) with in vivo efficacy and improved toxicity profiles compared with standard agents.

Authors:  Stephanie M Cohen; Ridhwi Mukerji; Abbas K Samadi; Xuan Zhang; Huiping Zhao; Brian S J Blagg; Mark S Cohen
Journal:  Ann Surg Oncol       Date:  2011-08-12       Impact factor: 5.344

4.  Development of novobiocin analogues that manifest anti-proliferative activity against several cancer cell lines.

Authors:  Joseph A Burlison; Christopher Avila; George Vielhauer; Donna J Lubbers; Jeffrey Holzbeierlein; Brian S J Blagg
Journal:  J Org Chem       Date:  2008-02-23       Impact factor: 4.354

5.  Exploiting conformational dynamics in drug discovery: design of C-terminal inhibitors of Hsp90 with improved activities.

Authors:  Elisabetta Moroni; Huiping Zhao; Brian S J Blagg; Giorgio Colombo
Journal:  J Chem Inf Model       Date:  2014-01-15       Impact factor: 4.956

Review 6.  Natural Product Inspired N-Terminal Hsp90 Inhibitors: From Bench to Bedside?

Authors:  Anuj Khandelwal; Vincent M Crowley; Brian S J Blagg
Journal:  Med Res Rev       Date:  2015-05-25       Impact factor: 12.944

7.  Modulation of Hsf1 activity by novobiocin and geldanamycin.

Authors:  Renaud Conde; Zachery R Belak; Manoj Nair; Ruth F O'Carroll; Nick Ovsenek
Journal:  Biochem Cell Biol       Date:  2009-12       Impact factor: 3.626

8.  The design, synthesis, and evaluation of coumarin ring derivatives of the novobiocin scaffold that exhibit antiproliferative activity.

Authors:  Alison C Donnelly; Jared R Mays; Joseph A Burlison; John T Nelson; George Vielhauer; Jeffrey Holzbeierlein; Brian S J Blagg
Journal:  J Org Chem       Date:  2008-10-22       Impact factor: 4.354

Review 9.  Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions.

Authors:  David S Hong; Udai Banerji; Bahareh Tavana; Goldy C George; Joann Aaron; Razelle Kurzrock
Journal:  Cancer Treat Rev       Date:  2012-11-28       Impact factor: 12.111

10.  Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of hsp90.

Authors:  Joseph A Burlison; Len Neckers; Andrew B Smith; Anthony Maxwell; Brian S J Blagg
Journal:  J Am Chem Soc       Date:  2006-12-06       Impact factor: 15.419

View more
  2 in total

1.  Management of Hsp90-Dependent Protein Folding by Small Molecules Targeting the Aha1 Co-Chaperone.

Authors:  Jay K Singh; Darren M Hutt; Bradley Tait; Naihsuan C Guy; Jeffrey C Sivils; Nina R Ortiz; Ashley N Payan; Shravan Kumar Komaragiri; Jazzmin Jovonna Owens; David Culbertson; Laura J Blair; Chad Dickey; Szu Yu Kuo; Dan Finley; H Jane Dyson; Marc B Cox; Jaideep Chaudhary; Jason E Gestwicki; William E Balch
Journal:  Cell Chem Biol       Date:  2020-02-03       Impact factor: 8.116

Review 2.  Assay design and development strategies for finding Hsp90 inhibitors and their role in human diseases.

Authors:  Monimoy Banerjee; Ishita Hatial; Bradley M Keegan; Brian S J Blagg
Journal:  Pharmacol Ther       Date:  2020-11-24       Impact factor: 12.310

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.